Compare Modine Manufacturing Company (MOD) vs Novavax Inc (NVAX) Price & Performance

Modine Manufacturing (MOD) trades at $192.35, down 1.19% on the day, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth driven by data center cooling demand, with Q2 2026 EPS beating estimates at $1.53 versus $1.30 expected. However, valuation metrics appear stretched with a P/E of 71.77 and EV/EBITDA of 35.15, while profit margins face pressure from supply chain constraints.

The outlook remains positive due to strong data center backlog growth and analyst consensus price target of $305, representing 59% upside potential. Key risks include execution challenges in scaling production and margin compression. With 77% of analysts rating MOD as Buy and no Sell ratings, Wall Street maintains bullish sentiment despite near-term volatility.

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.